Archives of Autoimmune Diseases

Multiple sclerosis (MS) is central nervous system (CNS) based disease. It is a chronic inflammatory demyelinating disease [1]. The main causes for MS are genetic and environmental factors. It is a disease of young people (median age of onset is around 28 years) but is lifetime and is often disabling; 50% of patients need a cane to walk 15 years after disease onset; and Worldwide more than 2.5 Million persons are affected.

CNS myelination is a well-known biological phenomenon related to increase in action potential conduction speed and synaptic integration. Demyelination or abnormal myelination has been related to seizures and epilepsy either in patients or animal models. Although its role in fastening action potential propagation has been confirmed, few additional biological functions of CNS myelin has been described.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that effects more than 1.3 million people in the United States. RA is an expensive disease that negatively impacts the patient’s quality of life. Inflammation of the synovial joints and destruction of articular cartilage and bones caused by RA can affect a patient’s ability to perform commonplace activities.

Rheumatoid arthritis (RA) is a chronic disease of yet unknown etiology causing joint tenderness, swelling, destruction and premature death. Extraarticular manifestations such as cervical spine involvement, bursitis, tendovaginitis, rheumatoid nodules, rheumatoid vasculitis, pulmonary fibrosis, and accelerated atherosclerosis - to name a few – may occur.

Rheumatoid arthritis (RA) is a chronic, autoimmune disease that is associated with local and systemic inflammation, resulting in chronic pain and physical function limitations that may negatively impact quality of life (QOL). Despite advances in pharmacological therapies, currently available treatment options may be associated with adverse events and come at a high price tag.

Rheumatoid arthritis (RA) is a chronic autoimmune disease that is associated with local and systemic inflammation, resulting in chronic pain and physical function limitations that may negatively impact quality of life (QOL). Despite advances in pharmacological therapies, currently available treatment options may be associated with adverse events and come at a high price tag.

Rheumatoid arthritis (RA) is a chronic autoimmune disease that is associated with local and systemic inflammation, resulting in chronic pain and physical function limitations that may negatively impact quality of life (QOL). Despite advances in pharmacological therapies, currently available treatment options may be associated with adverse events and come at a high price tag.

Rheumatoid Arthritis (RA) is a systemic, chronic, inflammatory and erosive joint disease. Due the systemic effect mediated by increased serum pro-inflammatory cytokines, RA patients often present changes in body composition.

In the last decades there has been considerable progress in treatment, significantly improving quality of life, outcome and prognosis of rheumatoid arthritis (RA). Therapy adherence is a cornerstone of improved outcome. However, recent studies have shown that adherence may be low in a considerable percentage of patients.

Complement proteins constitute a proinflammatory system of the innate immunity which bridges with the adaptive immunity. It comprises of a group of serum zymogens, complement regulatory proteins (Cregs) and receptors.

Rheumatoid arthritis (RA) is chronic inflammatory arthritis characterized by the inflammation of multiple joints and significant joint destruction and disability. It is the most common form of inflammatory arthritis that affects synovial joints.

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases characterized by inflammatory arthritis that may lead to destruction of bone and cartilage. While the primary manifestation of RA is swollen and tender joints, it is often associated with multiple coexisting conditions such as fibromyalgia, fatigue, and malaise.

A 36-year-old Hispanic male, with a history of ulcerative colitis (UC) presented to the inflammatory bowel disease (IBD) clinic for initial evaluation. Over the past six years, the patient had been treated for his UC with various therapies including prednisone, multiple mesalamine formulations, and budesonide but always discontinued therapy due to what he perceived were adverse drug reactions. He described onset of pruritic blisters, affecting his chest, abdomen, back, and arms.

Prevalence of common autoimmune diseases such as multiple sclerosis (MS), type 1 diabetes, rheumatoid arthritis, and inflammatory bowel disease and allergies such as food allergies or eczema affect approximately 20% of the human population.

Histamine-mediated allergic reactions were recognized as pivotal mechanisms in the onset and progression of diverse allergic disorders. Cetirizine, a second-generation H1 receptor antagonist, had been extensively evaluated for its efficacy in mitigating histamine-induced inflammation and hypersensitivity.

Objectives: Anemia is a frequent extra-articular manifestation of rheumatoid arthritis (RA) and has been linked to increased disease activity and poorer outcomes. This study aimed to evaluate the association between hemoglobin (Hb) levels and RA disease activity in a Middle Eastern population.

Leflunomide (LEF) is one of the most effective synthetic disease-modifying antirheumatic drugs (DMARD) which is widely prescribed for rheumatoid arthritis. But the safety issues of LEF makes its use compromised due to various side effects like hepatotoxicity, GIT disturbances, etc, and variable patient responses. 

This controlled cross-sectional study investigated the prevalence of different types of parentification in women with fibromyalgia (FM) compared to women with rheumatoid arthritis (RA), healthy controls (HC) and women with depression or anxiety disorder (AD). The study also examined associations with maladaptive interpersonal styles (subjugation, approval seeking, self-sacrifice). 

Background: There is limited data on the effectiveness and safety of vedolizumab for Indian patients, making this study the first focused evaluation of its use in this population.This prospective, multicenter, open-label phase IV study enrolled patients aged 18–65 with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), who received vedolizumab 300 mg IV at weeks 0, 2, and 6 (induction) and at weeks 14, 22, 30, 38, and 46 (maintenance).